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Section of Radtology 731 [June 16, 1944] DISCUSSION ON ADVANCED CASES OF CARCINOMA OF THE BREAST TREATED BY STILBOESTROL Dr. Frank Ellis, in opening the Discussion, said that the following points should be considered:
(1) Whether any effect is produced on the course of carcinoma of the breast by stilbcestrol.
(2) Whether age of patient or menopause exerts any influence orn this effect.
(3) Whether the response is affected by the histological and cvtological structure of the tumour.
(4) The dosage, including maintenance dose. if anv. (5) The svmptoms associated with its administratioin and the contra-indications to its use.
(6) Possible changes in the serum acid and alkalinie phosphatase suLch as are associated with improvement in carcinoma of the prostate.
Dr. Ellis reported on 21 cases of carcinoma of the breast in whiich the stilhcestrol effects were observed with no complicating influence of radiation. The dosage was relatively heavy-about 15 mg. daily. 3 cases showed complete intolerance to stilbcestrol. The youngest was 35 years of age and the oldest 81. The average age of the 4 who improved on stilboestrol was 64-2. 1 case was that of a male aged 69 with abdominal gland involvement. He received 15 mg. daily for three months. Ihis symptoms were unchanged.
In all cases the chief svmptoms were nausea, vomiting, activity of the breasts with tenderness, swelling and pigmentation of the areola, resumption of menstruation in a few cases (so severe in one case as to necessitate a blood transfusion) and cedema of the ankles. Of these the nausea and vomiting was always immediate, the others being delayed two to six months.
There was also in the cases which improved a definite feeling of well-being with a remarkable increase of appetite. Progress was assessed where possible by measurements. No phosphatase estimations could be carried ott.
Dr. S. Bryan Adams said that his series were all at an advanced stage for which other treatment was not available or not indicated. Thev represented a complete series and a selection had not been made in view of the results obtained.
The dosage varied from 1 to 15 mg. daily, the first case receiving only 1 mg. daily showed such a marked improvement that the dosage was not increased.
The oldest patient was 82 and the youngest 36. The average age was 62 3. The woman of 82 had nodular recurrences in left breast following a local excision four vears previously. After two months of stilboestrol treatnment (5 mg. t.i.d.) she showed marked improvement and no nodules were palpable.
Mr. G. W. Blomfield: 10 cases were treated at Sheffield, with doses varying from 2 mg. to 15 mg. per day. Some had nausea on snmall doses or large doses. Some were disturbed by the phvsiological actions of the drug when "menstruation" commenced again after the menopause. As a whole the side effects were not excessive and patients did not object to taking the drug when an explanation was given.
Accuirate assessment of the size and extent of the tumours was atteml)ted. In some cases histological sections were taken after treatmenit to determine whether the mitotic activity and microscopic appearance was affected.
There were 5 cases onlv where the growth could be accurately measurecd and where 10 mg. or more was given daily. No definite evidence of growth control could be found in these cases.
No striking results were met with in this series. It was interesting to note that ulceration of one growth healed IJp and the size of the tumours remained constant. Histological sections, however, showed no evidence of control: the cells were unaffected and mitoses were numerouis.
Dr. Alexander Haddow (Chester Beattv Research Inistitutte, Royal Cancer Hospital (Free)): This communication deals with 13 cases of advanced cancer of the breast. MIanv of these had previouslv received treatnment bv suLrgery, and showed recurrence, or had been treated bv high voltage therapv, although a sufficient interval had elapsed since such treatment to make anv confusing effect improbable.
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Stilb(tstrol was given in total doses varying from 75 mg. to 676 mg. over periods of treatment varying from four weeks to twentv-four weeks; the average total dose being about 350 mg. in an average treatment period of over eleven weeks. Administration was bv mouth, or by intramuscular injection, and in some cases by both routes. In cases showing some degree of response which could reasonably be attributed to the drug, the sequence of changes was characteristic. Lesions previously red in colour tended to develop a purplish discoloration or sometimes pallor. small skin nodules would show scabbing, or flattening, and occasionally disappeared, and larger nodules and masses might undergo partial regression Dr. Haddow showed 2 tables of which the following is a summary: Table I showed a classification of the response in these 13 cases, divided into three categories. In Group A (9 cases) the disease showed uninterrupted progress, being apparently quite unaffected except possibly to a very minor degree in 2 cases. In Group B, consisting of 3 cases, the disease also continued to advance, btut after a short period in which the breast tumour showed some retardation of growth, or partial regression, almost certainly attributable to treatment. Onlv the single remaining case manifested a marked and more lasting change, which has continued to the present date over a period of four months, an(d which consisted of a considerable degree of regression affecting both the primary tumour and secondary deposits in the axillarv lvmph no(des. Table IL showed the details of age, total dosage, and duration of treatment in the three classes. Age in Group A, that is in those patients showing little or no favourable response, varied from thirty-one years to sixty-eight years. Thle mean age in Groups B and C together, that is those showing a temporarily favoutrable or mlarkedly favourable response, is considerably higher than in Group A, 62 as against 48, that is a difference of fourteen vears. The numbers arc (of course very small, and no real conclusion can be drawn, but it mav be of interest that the difference in age between those showing no response, and those showing some favourable response, is statistically significant. This is mentioned merelv as a suggestion that favourable response may possibly be more likely in older and post-menopausal age-groups, and as an indication of the need for very much larger numbers before positive conclusions can be drawn.
Total dosage is essentially comparable in the different grouLps. Dutration of treatment is somewhat longer in those cases showing favourable response. This is perhaps not a significant feature, as experience has shown that response, where it occurs, has been evinced at an early stage (between one anid two months) after the commencement of treatment.
2 44 (immediately before treatment), (B) at 22 Fig. 1 gives a comparison of the local lesion in the most fa vaourable case at an snterval of fifteen weeks. In this case a spheroidal-cell carcinoma--a mini) in the breast was noticed by the patient in 1942, aind it so happens this it the only case of the series which had not received any form of treatment previoutslx Two points will be noted: (1) The pronounced regression of the prirnary tumour, andcl
(2) the areolar pigmentation due to the administeired ostrogen. In this (ase partial regression also occuLrred in a secondarv mass in the sxilla.
Examples of this kind, howexer exceptional, are of couirse both clinicaliv striking anid of the greatest fundamental importance. It shouLld clearly be one of the purposes of an investigation such as tlhis, which is only in its preliminary stages, to attempt to determine whether these highly favourable cases are simplv the exceptional responses which may be encountered in a uniform population, or whether thev represent a special type of breast cancer: that is, whether breast cancer. in its relation to stilbcestrol, represents a unitv, or comprises sexveral different cate-orics. This is information which can onlv be obtained from the investigation of conmparativelv large nuimbers.
If cancer of the breast is homogeneous, the relation may be (1) that the great majority of cases shov little response; (2) that most cases show a medium degree of response anld only small nuLmbers show either no response or a marked response; (3) an intermediate type where more cases show soine response than no response. If, on the other hand.
cancer of the breast (in this respect) comprises several categories, the distribution of responsive cases may be a composite one. To obtain this knowledge wouLld require, as well as large numbers, a mteasure of respon-se, as by some system of clinical assessment or marking. This in turn would involve close contact between thc various collaborators, so that their clinical criteria might be as uniform as possible. It is comparativelv easv to classifv the Jeast responsive and the most responsive cases: the main difficultv woldli arise from the classification of intermiie(liate grouips with me(lium degrees of response.
Response may possibly be correlated with anv one, or several, of a large number of factors, such as age (wvhich has already been discussed in a tentative way), dosage. duration of treatment, menstrual and reiproductive history, and so on. The present series is too small to allow any correlation wvith the histological or cytological nature of the tuLmour, yet this is ianother obvious factor of likely importance. A fuLrther possibility is that the metabolism of the ocstrogen may be different in different cases.
Dr. W. M. Levitt reported on 11 cases. 7 treated at St. George's aind 4 at St. Bartholomew's Hospital. All wvere advanced carcinoma of the breast, 7 had multiple skin andl suLbctutaneous deposits, 3 lhad 1bone del)osits and 1 chest deposits. The general condition was good in 7 cases in the series anid fairlv aoocd in the remainder. Dosage was standardized commencing with 2 5 mg. of stilbuestrol three times a dav and working up rapidly tG 5 mg. three times a day, at which level the dosage was maintained until death or the present time. In only 1 case was implrovement noted. This was a woman of 69 with a fungating ulcer. This ulcer became nmLuch cleaner and reduced in area from 66 sq. cm. to 20 sq. cm. The improvement has been maintained for four months although disease is still present. This was the only pltient over 60 in the series. None of the others was Improved and 5 are dead.
Dr. R. McWhirter: Up to May 1944 37 cases of carcinoma of the breast were treate(l with stilb(rstrol. All the patienlts had advanced disease. The dosage given was 5 mg. tvice a da).
Of the 37 cases treated 6 showed verv definite improvement. In the remainder the progress of the disease was not affected beneficiallv anid indeed in 2 cases the patients appeared to have been made worse by the treatniient. All 6 patients in whonm definite improx ement occturred were oxer 50. The average age was 62 years and the youngest wvas 52 vears.
The histological type was known in 4 and iii all 4 the tumouir vas uindifferen-tiated. On the other hand of the 2 cases apparently made worse bv stillhrstrol the histological tvpe was known in one and the tumour was well differentiated.
The improvement mav not be maintainied even when the stillxrstrol is contintled. In the first and third cases some deterioration has taken place.
Apart from the effects noted on the tuimour tissue the only point calling for commlrnenlt is that with the level of dosage used patieruts were rarely upset by the treatment. Only I patient was unable to continue the treatment on account of sickness. MIore recentlv. by the courtesy of NIessrs. Glaxo, dienoestrol has been tised and of the patients so treated none has suffered from sickness. Dienostrol is more potent than stilbxwstrol and 1 mg. of the former is equivalent to 3 to 5 mg. of still)(rstrol.
Dr. Edith Paterson reporte(d oIn 13 patienlts treated with stillxWstrol and also on a group of 23 patients treated with triphenylchloroethylene. All wvere advanced cases of breast carcinoma, and no case had had recent radiation treatment.
She said that triphenvlchloroethylenie. like stilboestrol. ivas a synthetic substance with the pharmacological action of the natural follicullar hormone of the ovary. Experience showed that the effect on the breast an(d also the si(le reactions on the patienit w ere similar vith the two (lrUgs.
Patients receiving either drug were classified as to whether their tumours showed measurable regression even if slight and temporary, whether their tumours remained stationary or whether the disease progressed during treatment. [Stationary and progressed cases are under "Not Improved" in table.]
In the cases treated by stilbeestrol a biopsy was obtained in all cases. In the 2 regressing cases a reduction in size of the tumour occurred and a considerable degree of epithelialization of the ulcer. No local treatment was used in these cases.
With stilboestrol the average length of treatment was 12-2 weeks and the average dailv dose was .58 mg. The average age was 56 2 years. With trichloroethylene the overall period of treatment and observation was longer and the doses of cestrogen were larger than in the stilbeestrol series. In over half the cases a biopsy was obtained. With triphenylchloroethylene the average length of treatment was twenty-seven weeks; the average daily dose was 3 g. The average age was 55 6 years.
Regression following either of the drugs was most marked in the established primary mass whether this was the original breast tumour or recurrent nodules on the chest wall. Bone metastases were also sensitive either regressing or ceasing to give pain (4 cases).
Secondary deposits in lynmph nodes seemed on the whole less sensitive and it was commonly observed that the original lesion could be regressing while fresh foci appeared in lymph nodes or in the opposite breast, or in the lungs.
Regression when it occurred could not be correlated with the size of the dose of either drug within the limits of dosage used. Nor was it associated with the length of time of treatment; cases which showed regression did so within a few weeks of the commencement of treatment. It is interesting that regression occurred in the only male case in the group.
Only one positive correlation was found. The pathological characteristics of tumours seemed related to the effects observed in that the more cellular tumours were the most responsive. No scirrhous tumour in either group showed any response and of the tumours actively progressing during treatment, the majority were scirrhous in type. The greater effect in the non-scirrhous type mav be dependent on the greater vascularity of the tumour so that the drug can more easily reach the malignant cells.
Neither drug would seem to have a curative value and neither is as effective or certain in its results as palliative X-ray therapy. The findings, however, are of scientific importance and should encourage an extended trial of other allied substances. Slides were shown illustrating the degree of regression in 3 cases and illustrating the histological changes in one tumour following treatment.
Dr. C. J. L. Thurgar: The 10 cases of carcinoma of the breast treated with stilbcestrol here reported are taken from a larger series of nearly 30 patients who have received the drug. The 10 are consecutive cases who have received a dosage of not less than 10 mg. a day, patients who coild not tolerate this amount having been excluded. The results obtained approximate closely to those in the series as a whole. The average age was 58-6. The voungest was 38 and the oldest 76.
Those cases which give a definite result appear to respond immediately and steadily. Objective improvement is apparent within one month of treatment bv stilboestrol.
The 10 cases above include 5 in whom stilboestrol exerted no influence on the natural course of the disease. 5 showed some improvement and these comprised: 1 (aged 58) rapid and spectacular response, 2 cases of definite and continued general and local improvement and 2 who were subjectively improved. but in whom the objective response was transient.
Of the possible factors involved, age seems to be the most important consideration. I have not observed any patient under the age of 58 who has shown any objective improvement to stilboestrol therapy and the majority of the patients who have shown any response have been well over 60. It may well be that those conditions which bring about regression of breast cancer on the administration of cestrogens depend upon the establishment of a balance in the ductless gland system which is only reached some years after the menopause.
The influence of dosage seems more difficult to determine. Though most of the earlier cases in my series were given 10 mg. or more daily, other patients, who were put on stilbcestrol by their family doctors before being brought to my notice, incluide several who manifested great improvement on very small dosage levels.
Other broad impressions which emerge are that little hone can be entertained from stilboestrol therapy for patients who are in very poor general condition or for those who have large recurrences in areas that have been irradiated to the limit of tolerance, though I have seen individual cases which refuted each of these generalizations One puzzling feature shown by a number of cases is the varying degree of response of ditTerent metastases in the same patient. Some deposits may even regress, while others enlarge or new ones appear. / In assessing the results of stillbestrol treatment, it must be borne in mlind that breast cancer is a form of malignant disease which sometimes shows spontaneous remissions or even regressions, though these are probably always temporary.
Dr. James Z. Walker (Radiotherapy Centre, County of Litcoln): The survey by Harvey and Dawson has indicated that the incidence of malignancy in all breast tumours became very high as the 40 to 60 age-period was 'reached. The following graph could be drawn from their If the graph for the age-period at which the 'menopause develops is added, tlien curve "C" can be drawn. The striking proximity of curve "A" and curve "C" is remarkable.
The cycle of events (climacterium) which brings about the menopause may last many years; the cessation of-menstruation is -onlya small arc in this cycle.
The onset of the climacterium would 'appear to be associated with either an atrophy or a dysfunction of the ovaries with the secretion of abnormal hormones (cp. thyrotoxicosis), which may result in a metropathia hacmorrhagica or other pathological process in the ovaries or uterus, &c:, and/or alternatively, this derangement or loss of normal ovarian function may bring about an alteration in the cellular activity of breast tissue which results in a mastopathia (so-called chronic mastitis, &c., all belong to this group of conditions). With the cessation of the menses, the ovarian cestrogernic hormones do not immediately disappear from the blood and urine, but do so in 80% of women within three years, about half of the remaining 20% do so subsequently and the rest perhaps not at all.
The atrophy of the ovaries may be associated with an over-secretion (or a failure of utilization, or neutralization) of the gonadotrophic hormones of anterior piptuitary origin (i.e. follicular maturation hormone, luteogenic hormone and prolactin). In this way, an imbalance develops between the various endocrine glands, resulting in a thyroid hypoactivity and probably a hyperactivity of the suprarenal cortex. This manifestation would seem to account for the vasomotor and blood pressure disturbances of the climacterium.
Metabolic activity of tissue cells becomes altered, gross manifestations of which show themselves as glycosuria, increased adiposity, &c.
From the foregoing it can be expected that the cellular activity of the breast, losing the control of ovarian (normal) ocstrogenic chemical substances, becomes abnormal and pathological, and, in certain areas, frank malignancy develops.
In the attempt to counter this process, it has been thought that by giving large doses of one of the ovarian cestrogenic substances (e.g. diethyl stilboestrol), one could restore this normal balance between anterior pituitary, thyroid, suprarenal, and ovarian hormones, and, by so doing, either destroy breast malignancy or, alternatively, set up a state of affairs in which breast cancer cells are incapable of survival. If cancer of the breast is due to a chemically abnormal substance, either produced by ovary or anterior pituitary (or elsewhere), the saturation of the body with a normal ovarian hormone will either neutralize this substance or, by virtue of its concentration, prevent it from acting on mammary tissue.
One line of attack on the problem is to assume that cancer of the breast is due to ovarian activity (normal or pathological) and that castration is of considerable benefit OCT. in the control of the disease. The other is that it is the loss of ovarian function that allows endocrine substances of non-ovarian origin to have-unrestrained action on breast tissue. On this second assumption, the purpose of this test is based: 10 cases of breast cancer were chosen, and notes made on how they have responded to daily doses of diethyl stilbcestrol.
The dosage varied frors, 1-2 mg. t.i.d. to 10 mg. t.i.d. This latter dose was well tolerated ih a woman aged 64 with involvement of both breasts and axillce.
There was no complete cure in the 10 cases. The average age of the 3 who were considerably improved was 67-3 years. The treatment was of no value in 5 cases, whilst in 2 cases there was an adverse effect. In the case of carcinoma of male breast (aged 71) the effect of the stilboestrol was to cause increased cellular activity of the breast cancer.
Professor B. W. Windeyer: My 10 cases were all cases of advanced carcinoma of the breast. 2 of them had had no previous therapy. The remainder had all had previous tieatment, -surgical removal in 5 cases and X-ray therapy to the primary lesion or to recurrences or metastases in 7 cases. Skeletal metastases were present in 3 cases. Pleural effusion was present in 2. They are, therefore, a series of very advanced cases.
The period of observation was on the average of five months' duration. Of the 10 cases, 3 showed demonstrable improvement.
In none of the 10 cases has there been complete clinical disappearance of the growth, but 3 have improved. In 4 cases no improvement has been noted and the disease has extended.
In the final 3 cases there has been no demonstrable clinical change since treatment was started. It is possible that there has been some retardation of the growth.
Stilbcestrol would appear to have had some effect in causing regression or retardation of growth. Its action, however, is uncertain and it has not caused complete disappearance of the disease in any case.
Professor E. C. Dodds: Stilboestrol was produced as a substitute for cestrone and cestradiol and for experimental work of academic interest on the specificity of the cestrogenic reaction. It fulfilled all these expectations, and in addition it was found to control the symptoms of carcinoma of the prostate. If it has any action on cancer of the breast, this must be regarded as a kind of "pourboire". I am surprised that the doses given have not been much heavier in an attempt to evaluate whether the failure in a number of cases is due to a lack of sensitivity to the drug. It would also be interesting to try the other two synthetic cestrogens, namely hexoestrol and dienoestrol. The latter is a more powerful cestrogenic substance when administered by mouth. The definite improvement in a number of cases in women of menopausal and post-menopausal age requires very careful reviewing. The general systemic effect of oestrogens in the menopause is very striking and there is an immediate improvement in the woman's general condition and particularly a feeling of well-being. This must be allowed for. Finally, if the very excellent suggestion made by the Chairman is carried out-namelv that the work should be continued--would it not be advisable to perform a rigid series of controls? Under spectacular improvement are classified cases of which the following are typical: Ellis, Casea V. and VII. The breast tumour rapidly disappeared in both cases. The affected axillary glands also disappeared in Case V. In Case VII the axillary mass was reduced to one-fifth of its size. * One male breast.
